Monitor upcoming FDA and PMDA interactions in Q2 2026 as potential catalysts, but be cautious due to lack of revenue, sustained losses, and limited cash runway that may necessitate dilutive financing.
Price Chart
Executive Summary
BioCardia reported its 2025 financial results, showing no revenue and a net loss of $8.2 million, with cash of $2.5 million. The company highlighted clinical progress in its CardiAMP and CardiALLO programs, including positive echocardiography data in heart failure and upcoming regulatory milestones with the FDA and PMDA, but continues to operate at a loss with minimal financial resources.
Key Financial Metrics
Key Facts
- No revenue in 2025 vs. $58,000 in 2024
- Net loss increased to $8.2 million in 2025 from $7.9 million in 2024
- Cash and cash equivalents totaled $2.5 million at year-end 2025
- R&D expenses rose to $5.0 million, SG&A fell to $3.3 million
- Positive blinded core lab data from CardiAMP HF trial showed reduced pathological remodeling in prespecified subgroup (p=0.02 and p=0.01)
- FDA accepted Helix catheter Pre-Submission; meeting scheduled in Q2 2026
- PMDA granted preliminary consultation on CardiAMP approval in Japan
- Company plans Q-Sub filing with FDA for CardiAMP approval based on elevated biomarker subgroup
Financial Impact
Increased net loss of $8.2 million on zero revenue, with only $2.5 million cash remaining
Risk Factors
- Very low cash balance ($2.5M) relative to annual operating burn (~$7.4M)
- No revenue and increasing net losses raise going concern risks
- Clinical development progress does not offset deteriorating financial fundamentals
- Potential for near-term dilution or failure to secure funding
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3261730 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | 8-K | $0.8975 $1.04 | ▲ +15.88% | ▲ +15.54% | $0.9000 (+0.28%) |
Oct 19, 2026 7d ago | Press Release | $0.9000 $1.04 | ▲ +15.56% | ▲ +15.22% | $0.9000 (−0.00%) |
Oct 7, 2026 19d ago | 8-K | $1.09 $1.06 | ▼ −2.75% | ▼ −2.33% | $0.9000 (−17.43%) |
Oct 1, 2026 25d ago | 8-K | $1.02 $1.04 | ▲ +1.96% | ▲ +1.22% | $0.9000 (−11.76%) |
Oct 1, 2026 25d ago | Press Release | $1.02 $1.04 | ▲ +1.96% | ▲ +1.22% | $0.9000 (−11.76%) |
Sep 23, 2026 4w ago | 8-K | $1.05 $1.07 | ▲ +1.90% | ▲ +1.99% | $0.9000 (−14.29%) |
Sep 23, 2026 4w ago | Press Release | $1.05 $1.07 | ▲ +1.90% | ▲ +1.99% | $0.9000 (−14.29%) |
Sep 10, 2026 6w ago | 8-K | $1.10 $1.08 | ▼ −1.82% | ▼ −2.67% | $0.9000 (−18.18%) |
Aug 24, 2026 9w ago | 8-K | $1.06 $1.13 | ▲ +6.60% | ▲ +6.28% | $0.9000 (−15.09%) |
Aug 5, 2026 11w ago | Press Release | $0.9500 $0.9496 | ▼ −0.04% | ▲ +0.12% | $0.9000 (−5.26%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers